US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(OP:
BNXTF
)
0.2700
UNCHANGED
Delayed Quote
Updated: 1:55 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BNXTF
< Previous
1
2
3
Next >
BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study
March 14, 2024
Via
Investor Brand Network
Topics
Intellectual Property
BioNxt Reports Successful Results From ODF Cladribine PK Study
March 12, 2024
Via
ACCESSWIRE
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
February 07, 2024
Via
ACCESSWIRE
BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
December 12, 2023
Via
ACCESSWIRE
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
October 27, 2023
Via
ACCESSWIRE
BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
November 20, 2023
Via
ACCESSWIRE
BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
November 15, 2023
Via
ACCESSWIRE
BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
November 13, 2023
Via
ACCESSWIRE
BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
August 02, 2023
Via
ACCESSWIRE
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
May 15, 2023
Via
ACCESSWIRE
BioNxt Successfully Completes Pilot Study for Contract Development Customer
May 09, 2023
Via
ACCESSWIRE
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company
April 24, 2023
Via
ACCESSWIRE
BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity
April 17, 2023
Via
ACCESSWIRE
BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology
March 07, 2023
Via
ACCESSWIRE
BioNxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson’s Disease
March 01, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
